Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Quest PharmaTech and US based Hemispherx Biopharma have entered into a clinical development arrangement to evaluate the clinical utility of combining Quest's antibody immunotherapy technology with Hemispherx's immune activator in a thirty patient clinical trial.
Subscribe to our email newsletter
As per the agreement, Quest and Hemispherx will equally share the clinical trial’s expenses.
Hemispherx will offer technical expertise and relevant data to support the regulatory process necessary for organizing the clinical trial.
Hemispherx will also store and maintain clinical supply inventory of Oregovomab at its manufacturing facility in New Brunswick.